Steven’s shoulder still hurt. At 48 years old, he had fallen off his mountain bike and suffered a rotator cuff injury with persistent pain despite 8 weeks physical therapy, NSAIDs and activity modification. Now he was asking for the Wolverine stack. BPC-157 and TB-500, drawn into the same syringe, with the unspoken assumption that they’re equally validated, equally safe, two interchangeable halves of one proven whole. In Part 1, using Steven as a case study, I walked through the clinical decision framework I apply for any patient asking about an experimental therapy.

In this article, I want to focus on the one I think deserves more skepticism than it’s getting during the month its fate is being decided in Washington DC: TB-500.

Quick recap of the clinical decision-making framework for anyone joining mid-series:

Safety × 2 → Affordability → Efficacy → Effectiveness

Each gate must be passed before we move to the next. The full explanation of why is in Part 1.

Here’s the breakdown for TB-500, running through all the gates.

Subscribe now

Safety- 2 questions

Question #1: What do we know about the safety of the molecule?

Question #2: What do we know about the manufacturing process? Is what’s in the vial the same as what’s on the label?

For question one, this is where this compound’s story gets interesting and where I think the reputation and the evidence quietly split apart. For question two, TB-500 has the identical gray-market sourcing problem I’ll describe for BPC-157 in Part 3 of this peptide series. Compounding pharmacies operating in a legal gray zone, research-chemical suppliers with no meaningful oversight, “certificates of analysis (COAs)” that function more as marketing collateral than regulatory documents. That section applies to TB-500 verbatim, so I won’t re-run it here.

Question #1: Molecular Safety

Start with the genuinely good news. The human safety record for this molecule’s family is strong: more than 80 healthy volunteers dosed intravenously across two placebo-controlled trials(1,2), at doses well above anything used for an injury, with side effects that were mild, short-lived, and no more common than placebo. The same molecule has also been given to heart-attack patients and used as eye drops for corneal healing, again without safety signals.

Here’s the catch, and it isn’t small: almost none of that safety record belongs to TB-500. It belongs to Thymosin Beta-4 which is the 43-amino-acid protein your own cells produces naturally, originally isolated from bovine thymus tissue.(3) TB-500 is a different molecule: a synthetic seven-amino-acid fragment of the parent molecule, Ac-LKKTETQ, chemically characterized specifically because anti-doping labs needed a way to detect it(4), not because anyone had run a clinical trial on it. It’s manufactured for stability and sold in a vial for subcutaneous injection. Same family but a fragment given at a different dose, in a different route of administration and not tested.

There is not one published human trial of the TB-500 fragment itself, for any condition, at any dose. So when you read that “TB-500 is well studied and safe,” what’s actually being cited every is the safety record of its larger, natural parent, quietly relabeled and attributed to the smaller synthetic one. Most advocates aren’t lying. They’re assuming the synthetic fragment will behave similarly to the parent natural form Thymosin Beta-4. That’s a big leap of faith. This is a classic example of what is called “drug class” effect bias.(5) By way of example, researchers took the same approach with human growth hormone: isolating a 16-amino-acid fragment from its C-terminus (AOD-9604) to capture hGH’s fat-burning effect without its growth-promoting, IGF-1 risks. The fragment turned out to be safe but in controlled trials, it never reproduced the parent hormone’s benefits, and development was ultimately discontinued.(6)

The safety record everyone cites for TB-500 belongs to the parent molecule, studied a different way, at a different dose. It’s not only a mistake, but also plainly arrogant and dangerous to assume the same safety and benefit profile.

There’s a second wrinkle TB-500 advocates skip over because it doesn’t fit the narrative. The same biology that makes this peptide good at healing i.e. cell migration, and new blood vessel formation (angiogenesis) is the same biology that tumors are especially good at exploiting. In human tissues, higher natural levels of endogenous Thymosin Beta-4 have been associated with increased risk of cancer metastasis and reduced survival.(7,8,9) This does not prove injecting TB-500 causes cancer; however, it does suggest the growth-and-migration signaling the parent molecule triggers has a documented dark side in oncology and no one has bothered to study if the synthetic fragment behaves similarly. Therefore, if you have a personal or family history of cancer, or you’re in active treatment, this belongs in a conversation with your physician; this is not a footnote you scroll past.

One more finding worth knowing, because it complicates the story rather than resolving it: a lab tissue and rat model study(10) found that TB-500 itself didn’t appear to drive wound healing directly; rather one of its metabolites did. If that holds up under replication, it suggests the peptide you’re injecting may function as something closer to a pro-drug: inactive until your body converts it into something else. That doesn’t mean TB-500 doesn’t work. It means we don’t know why or how it might work which is an uncomfortable thing to admit about a compound this widely used.

In addition, for TB-500 itself we have no long-term human safety data at any dose, no study of the BPC-157 + TB-500 combination in people, and a WADA S0 prohibited-list classification for any competitive athlete. The “molecular safety” for TB-500 is unstudied in its actual injected form, and resting on a level of reassurance extrapolated and cherry picked from its parent molecule Thymosin Beta-4.

Share

The Regulatory Moment This Is Publishing Into

Here’s why the timing of this article isn’t incidental. In April 2026, the FDA formally removed TB-500 along with BPC-157 and ten other peptides from its Category 2 restricted compounding list, after the companies that had originally nominated them for that list withdrew their nominations. That sounds like a green light. It isn’t one. Removal from Category 2 does not place a substance on Category 1, the list a licensed 503A compounding pharmacy is authorized to prepare from. TB-500 currently sits in a genuine regulatory gray zone: no longer flagged as a significant safety risk, but not yet cleared for compounding either.

That gray zone has an expiration date. On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) meets to review seven peptides for possible inclusion on the Section 503A Bulk Drug Substances List.(11) The actual legal precondition required for a compounding pharmacy to prepare a substance for prescription. TB-500 is on the agenda for day one, alongside BPC-157, KPV, and MOTS-C. The FDA has opened a public docket for this meeting, FDA-2025-N-6895,(12) and it is accepting comments right now: anything submitted by July 9 is guaranteed to reach the committee before it votes, and the docket closes entirely on July 22.

I want to be precise about what a favorable vote would and wouldn’t mean, because I’ve already seen this oversold. A PCAC recommendation is advice to the FDA, not a rule. The agency would still need to complete formal rulemaking before any pharmacy could legally compound TB-500 again. This is a process that, based on how these things typically move, likely pushes real patient access into late 2026 at the earliest, and plausibly into 2027. If you’re a patient, a prescriber, or simply someone who thinks this process deserves scrutiny in either direction, the docket is open to you right now, and it will not stay open much longer.

By the time you read Part 3 of this series, the country may already have a preliminary answer on whether TB-500 gets a legal path back into compounding pharmacies. The evidence base won’t have changed by a single study between now and then.

Affordability

A typical injectable TB-500 protocol, sourced from a compounding pharmacy is 500–1,000 mcg per day, or 2500 mcg dosed once to twice weekly; over an 8- to 12-week course, running $250–$500 a month. You may find research-chemical suppliers selling it for less because they are not required to follows the safety guidelines that are required of legitimate compounding pharmacies. A lower price from an unverified supplier isn’t a deal. It’s a different risk profile, and you’re the one absorbing it. None of this is covered by insurance.

Effectiveness: What is the Evidence?

The Molecule and Plausible Mechanisms

TB-500 is marketed as the commercially available fragment of Thymosin Beta-4, a peptide found in virtually every human and animal cell. The proposed mechanisms are genuinely coherent: it binds G-actin and regulates cytoskeletal dynamics, which matters for cell migration and wound repair; it appears to downregulate inflammatory cytokines; it promotes angiogenesis (improving blood flow) at the injury site; and it appears to help recruit progenitor cells to sites of tissue damage. While the biology is plausible, no one has tested the parent molecule nor TB 500 for musculoskeletal issues in humans.(13)

Two more animal studies are worth naming specifically, because they’re the strongest data and because they still make the case for caution. In a rat knee-ligament model, researchers reported that Thymosin Beta-4 treatment produced better-organized collagen and measurably stronger tissue at four weeks.(16) In a mouse fibular fracture model, a separate study found that treated calluses developed roughly 40% greater peak force to failure than controls.(17) Both are real, and both are encouraging as biology; however, both only used the full-length parent molecule, delivered locally or systemically in a fracture-healing context. This is dramatically different context then injecting TB-500 subcutaneously for a soft-tissue tear.

Two features run through essentially all of this literature, and they cut directly against the compound’s reputation. First: almost every musculoskeletal study uses the full-length parent molecule, not the TB-500 fragment. Second: the results that look best used local delivery directly into the injury site(14), or chronic dosing in a Duchenne Muscular dystrophy disease model (15), and not a subcutaneous shot for an acute tear, which is how Steven and virtually everyone is actually using it.

What’s most interesting is advocates of the Wolverine stack treat TB-500 as the better-studied, more-proven half of the two compounds. For a tendon injury like Steven’s, that’s backwards. BPC-157 which I cover in full in Part 3 has direct, systemic, functional-recovery data in a tendon-to-bone rat model and a rotator-cuff model. TB-500’s best musculoskeletal outcome data is in a ligament, using local delivery of a different, larger molecule, and its muscle data moved a marker without improving clinically relevant function. Neither compound has a single human outcome study in tendon, muscle, or ligament. But only one of them is being oversold as though it does.

The half of the stack everyone assumes is better proven, TB-500 is the half with the thinner outcome data. Misinformation is rampant. Reputation does not equate to truth, and the gap between them is exactly where the Wolverine stack’s mythology lives.

Subscribe now

Where Does This Leave Steven and Us?

Based on these findings, I recommend against using TB-500 for Steven and for essentially anyone in his position. While the biology is plausible, the specific peptide being sold to him, the 7-amino-acid fragment in the vial, has never been tested in an animal musculoskeletal model, let alone a single human being, and the evidence base cited in its defense belongs to a molecule he isn’t actually taking. Furthermore, that naturally occurring parent molecule is correlated with increased risk of cancer metastasis, which is a red flag safety concern that demands further study before introducing it into the population.

What We Still Don’t Know

● We do not have a single published human trial of the TB-500 fragment itself, for any condition, at any dose.

● We do not have RCT data on TB-500 for any musculoskeletal indication, in the fragment let alone the parent molecule.

● We do not know the clinical significance, if any, of the parent molecule’s cancer-association literature for someone injecting the synthetic fragment.

● We do not know the long-term safety profile of repeated or chronic TB-500 use in humans.

● We do not yet know how the July 2026 PCAC review will resolve, or how quickly compounding access would follow a favorable vote.

The Takeaway From Part 2

TB-500 is biologically plausible and commercially popular, and neither of those facts makes it proven. The safety reassurance you’ve heard belongs mostly to a different molecule and leaves out the cancer risk concerns. The fragment being sold to you in the exact vial the Wolverine stack calls for, has never once been tested in a human being. I recommend against using it, not forever, and not out of alarm, but until the evidence catches up to the reputation, or until the FDA’s own review process identifies unpublished data that gives us something more concrete to work with than reputation.

In Part 3, I make the case for the other half of the stack, the one with an actual rat study that reversed what a corticosteroid injection does to a healing tendon, and a human evidence base I can describe honestly in one sentence: 544 studies, and exactly one of them in humans.

Before you read Part 3: What has been your experience using TB-500 or the Wolverine stack? Iif a compound’s reputation and its evidence base pointed in opposite directions, would you want to know? Tell me in the comments. I read every one.

Leave a comment

References

Numbered in order of first appearance in the text.

1. Ruff, D., Crockford, D., Girardi, G., and Zhang, Y. “A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers.” Annals of the New York Academy of Sciences. 2010;1194:223-229. doi:10.1111/j.1749-6632.2010.05474.x

2. Wang, X., Liu, L., Qi, L., et al. “A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.” Journal of Cellular and Molecular Medicine. 2021;25(17):8222-8228. doi:10.1111/jcmm.16693

3. Low, T.L., Hu, S.K., and Goldstein, A.L. “Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations.” Proc Natl Acad Sci U S A. 1981;78:1162-1166. doi:10.1073/pnas.78.2.1162

4. Esposito, S., Deventer, K., Goeman, J., Van der Eycken, J., and Van Eenoo, P. “Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.” Drug Testing and Analysis. 2012;4(9):733-738. doi:10.1002/dta.1402

5. Furberg, C.D., and Psaty, B.M. “Should evidence-based proof of drug efficacy be extrapolated to a ‘class of agents’?” Circulation. 2003;108(21):2608-2610.

6. Hainer, V., and Hainerová, I.A. “Do we need anti-obesity drugs?” Diabetes/Metabolism Research and Reviews. 2012;28:8-20. doi:10.1002/dmrr.2349

7. Cha, H.J., Jeong, M.J., and Kleinman, H.K. “Role of thymosin β4 in tumor metastasis and angiogenesis.” Journal of the National Cancer Institute. 2003;95(22):1674-1680. doi:10.1093/jnci/djg100

8. Ji, P., Diederichs, S., Wang, W., et al. “MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer.” Oncogene. 2003;22:8031-8041. doi:10.1038/sj.onc.1206928

9. Hall, A.K. “Differential expression of thymosin genes in human tumors and in the developing human kidney.” International Journal of Cancer. 1991;48:672-677.

10. Rahaman, K.A., Muresan, A.R., Min, H., et al. “Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.” Journal of Chromatography B. 2024;1235:124033. doi:10.1016/j.jchromb.2024.124033

11. U.S. Food and Drug Administration. “July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.” FDA Advisory Committee Calendar. fda.gov.

12. Federal Register. “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments — Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List.” Docket No. FDA-2025-N-6895. Published April 16, 2026. federalregister.gov.

13. Mendias, C.L., and Awan, T.M. “Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.” Sports Medicine (Auckland, N.Z.). 2026. doi:10.1007/s40279-026-02437-0

14. Xu, B., Yang, M., Li, Z., et al. “Thymosin β4 enhances the healing of medial collateral ligament injury in rat.” Regulatory Peptides. 2013;184:1-5. doi:10.1016/j.regpep.2013.03.026

15. Spurney, C.F., Cha, H.J., Sali, A., et al. “Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin β-4 in the dystrophin deficient mouse.” PLoS ONE. 2010;5(11):e8976. doi:10.1371/journal.pone.0008976

16. Ehrlich, H.P., and Hazard, S.W. “Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts.” Annals of the New York Academy of Sciences. 2010;1194:118-124. doi:10.1111/j.1749-6632.2010.05483.x

17. Brady, R.D., et al. “Thymosin β4 administration enhances fracture healing in mice.” Journal of Orthopaedic Research. 2014;32(10):1277-1282. doi:10.1002/jor.22686

18. Delcourt, V., Garcia, P., Chabot, B., et al. “TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs.” Drug Testing and Analysis. 2023;15(4):458-464.

Subscribe now

ABOUT THIS SERIES

Part 1 — Framework: How to Evaluate Emerging Therapeutics

Part 2 — TB-500: Borrowed Data, Live Regulatory Review (you are here)

Part 3 — BPC-157: The Half of the Stack With Actual Outcome Data

.

He’d taken a bad fall on his mountain bike. The MRI showed a moderate rotator cuff injury with two partial-thickness tears and tendinosis. He did exactly what he was told by a sports medicine physician: anti-inflammatory medications, modified activity, targeted physical therapy for six weeks. He worked hard at it.

Then he came to see me, still wincing when he tried to lift his carry-on into the overhead bin.

He’d done his homework, the way patients do now. He’d been using AI, reading forums, listening to podcasts, talking to friends at the gym. He came in with a question I’m hearing daily:

“Doc, should I try the Wolverine stack? Or is there something else I should be doing?”

Subscribe now

The Wolverine stack is a combination of peptides, most notably BPC-157 and TB-500, that has developed an almost mythic reputation in athletic and biohacking communities for accelerating healing. I’ll get into the evidence for that, and the meaningful gaps in it, in Part 2 of this 3-part series.

But before we could get there, I walked Steven through a conceptual framework: how do we evaluate a therapy when the data are limited? This is the world we’re increasingly living in. Patients aren’t waiting for the clinical trials to catch up to the stories they hear from influencers and friends. The responsible answer isn’t simply “we don’t know enough yet.”

This essay is that framework.

MEET THE PATIENT, AND WHY HIS BASELINE MATTERS

Before we talk about any treatment, I want to share something that most clinical conversations miss. We spend all our energy evaluating the therapy and almost none evaluating the terrain it’s being deployed into. The patient.

His labs and metrics told a story:

Steven, like many hard-working men in midlife, has been burning his candle at both ends for two decades on the same habits that got him through college and his twenties. Only now he’s approaching fifty and his intrinsic resilience is waning. His labs tell it all: excessive fat around his organs, metabolic impairment, chronic inflammation, and testosterone deficiency compounded by insufficient restorative sleep.

I say all this not to shame him, but because it is clinically essential. You cannot evaluate a healing therapy in isolation from the biology it’s entering. Steven’s healing capacity is already compromised before we add or subtract anything. That matters enormously for everything we do next.

It’s worth spending a moment on sleep specifically. Almost 70% of growth hormone output in men occurs during deep sleep. GH stimulates protein synthesis, cell regeneration, and cell reproduction, the anabolic processes that underlie tissue repair. Deep sleep also creates a unique endocrine environment, with low cortisol and elevated aldosterone, GH, and prolactin, that together foster the adaptive immune response critical to rapid and complete healing.

Health is like a garden. You can bring the best seeds, the best fertilizer, the best irrigation system, but if the soil is depleted and acidic, your yield will be modest at best.

Share

STEP ONE: ARE THERE PROVEN OPTIONS WE HAVEN’T EXHAUSTED?

The first question I ask when a patient asks about an experimental therapy is not “is it safe?” It’s more basic than that: do we already have something proven that could do this job?

For an acute rotator cuff injury, the conventional first-line protocol is NSAIDs, modified activity, and targeted physical therapy for six weeks. If that fails, the options are corticosteroid injection; regenerative medicine physicians may recommend PRP, stem cells, or exosomes. Steven had completed first-line therapy without a satisfactory healing response and was now deciding between a steroid injection and other options.

Before we went further, I wanted to pause on something we too often gloss over: the risks of the medications we consider standard of care.

NSAIDs: The Risks We Normalize

Ibuprofen and naproxen are so common that patients and clinicians alike treat them as essentially harmless. They are not. Here’s what the data show for regular ibuprofen use:

That last row deserves a moment.

NSAIDs carry a 220% increased risk of heart attack, highest in the first weeks of use, precisely when we prescribe them most aggressively. We call peptides ‘experimental’ and hand out ibuprofen like breath mints. That asymmetry should bother us.

For a 48-year-old man with insulin resistance and a chronic inflammatory state, that is not an abstract statistic. I’m not saying don’t use NSAIDs. I’m saying that when we reflexively reach for them while treating peptides as the ‘risky’ option, we owe it to patients to be honest about the risk profile of the thing we consider routine. This is the standard against which we’re comparing, and it is rarely risk-free and never 100% effective.

STEP TWO: THE SAFE SEQUENCE

When a patient asks about an experimental therapy, one where the clinical trial data are limited, incomplete, or absent, I work through a specific sequence. Not all at once, and never in the wrong order. The order matters.

Each gate must be passed before we move to the next.

Safety: A Two-Part Question

Safety is the first gate, and it’s binary: if a therapy fails here, we stop. But safety is actually two distinct questions that I see conflated constantly.

The first is molecular safety. Is the compound itself biologically harmful? What’s the mechanism of action? What do the animal studies show? What human data exist? Have Phase 1, 2, 3, or 4 clinical trials been published? If not, what are the theoretical risks based on what we know about the biology?

The second is quality assurance, and this is the one that gets almost no airtime in these conversations. Even if BPC-157 is molecularly safe, and the animal data are reasonably reassuring, what are you injecting? Most peptides in the current gray market come from compounding pharmacies operating outside FDA oversight, or from research chemical suppliers with no meaningful quality controls. Purity, potency, sterility, contaminants, adulterants: none of it is guaranteed. A safe molecule from a compromised source is not a safe therapy. The molecule and the manufacturing are separate risk variables, and both must be evaluated.

Affordability: Before Efficacy, Not After

Why does cost come before whether it works? Because a therapy that works in a clinical trial only works for your patient if your patient can actually take it long enough to get the benefit. Adherence is everything. A treatment that costs $400 a month and gets abandoned after six weeks because of financial strain was a waste of time and money. I’d rather have a frank conversation about cost upfront than discover three months into a treatment plan that someone has been rationing their doses.

Efficacy: Does It Work in the Trial Population?

Now we get to the question everyone leads with: does it work? The honest answer, for most peptides, is that we have compelling animal data, limited early human data, and a massive gap where the rigorous clinical trials should be. Physicians will often say peptides don’t work when they should say there is an absence of data examining effectiveness. These are not the same thing. The absence of evidence is not evidence of absence, and physicians confuse the two concepts regularly when speaking with patients. That confusion costs people real options.

BPC-157 has over 500 published studies. Almost all of them are in rodents. There is one published clinical trial in humans. That’s the evidence base we’re working with. It may be promising and also not yet proven, and conflating those two things does patients a disservice.

Effectiveness: Does It Work for This Specific Patient?

This is the distinction that rarely gets made, and the one I care most about as a clinician. Efficacy is what a drug does in a trial population. Effectiveness is what it does for the person sitting in front of me.

Trial populations are not representative populations. They’re often younger, healthier, less metabolically compromised, and more frequently male and Caucasian than the real patients asking about these therapies. A 30-year-old male athlete in a peptide trial and a 48-year-old with insulin resistance, low testosterone, chronic inflammation, and poor sleep are not biologically the same patient. Whether a therapy that worked in one will work in the other is genuinely an open question.

Age, hormonal status, metabolic health, sleep quality, the specific injury and the specific outcome desired: all of these modulate the answer. We must be honest about that uncertainty rather than extrapolating as if it doesn’t exist.

STEP THREE: KNOW YOUR PATIENT AND KNOW THEIR RISK PSYCHOLOGY

Once I’ve worked through the framework above, I turn to the individual. The same therapy can be the right call for one patient and the wrong one for another, even with identical lab values. There are two things I always name explicitly, because if I don’t, they operate invisibly.

Generalized Risk Tolerance

Some people are constitutionally comfortable with uncertainty. They’re the early adopters, the N-of-1 experimenters, the ones who read the forum threads and decide they’re willing to try something. Others are equally intelligent and engaged, and simply not wired that way. No amount of framing will make them comfortable acting on limited data. Neither disposition is wrong, but it must be named, because it changes the conversation entirely. If I don’t ask, I’m guessing. And guessing about risk tolerance is how patients end up either paralyzed by information that was meant to help them, or charging ahead with something they were never actually comfortable with.

The “My Buddy Tried It” Heuristic

This one is everywhere, and it’s powerful precisely because it feels like evidence. Your friend, your training partner, the guy on the podcast took BPC-157 and their injury resolved. It’s natural to assume it will work for you.

Psychologists call this a representative heuristic: we anchor our perceived personal risk to the anecdotal outcomes of people we know. The problem is that anecdotes, however vivid and compelling, are not data. The people whose injuries didn’t resolve after peptides are not posting enthusiastically on the forums. The selection bias is enormous.

I’m not dismissing anecdotes. They’re how great clinical hypotheses get generated. But they need to be contextualized rather than treated as proof, and naming this explicitly is part of my job.

The Risk/Reward Ratio: Quantify Where You Can, Be Honest Where You Can’t

Where data exist, I quantify. Where they don’t, I name the uncertainty and I’m specific about what kind of uncertainty it is. There is a meaningful difference between “we have no evidence this causes harm” and “we have evidence this doesn’t cause harm.” The first is a data gap. The second is a reassurance. We should not use the same language for both.

Leave a comment

WHAT WE DID: A TWO-PRONGED APPROACH

Once we worked through all of the above together, here’s what we decided. I want to focus on the sequencing, because it reflects the framework.

We did not lead with peptides, we led with the soil.

Prong One: Optimize the Healing Terrain

This patient’s healing capacity was compromised along multiple axes, and common sense says you fix the underlying environment first. This step is almost universally skipped in clinical practice because it’s slower, harder to bill for, and less immediately satisfying than writing a prescription. We skipped nothing.

Sleep architecture. His 45 minutes of deep sleep per night was the single most important number on his labs and the least discussed. Deep sleep is when the anterior pituitary releases its primary nocturnal growth hormone pulse, the anabolic and repair signal that drives tissue regeneration, immune surveillance, mitochondrial cleanup, and the brain’s own detoxification system. He was getting roughly half of what he needed. We addressed this directly: an Eight Sleep Pod to optimize mattress temperature, an evening moving meditation practice to bring the parasympathetic nervous system online before bed, and a hot bath with magnesium salts, which has a genuine sedative mechanism, lowers blood pressure, reduces muscle tension, and improves sleep onset.

Hormonal optimization. His free testosterone of 35 pg/mL is low-normal for his age, but low-normal is doing too much heavy lifting. Testosterone is directly anabolic to tendon and muscle tissue. The reason his is low isn’t just age: excess body fat drives elevated aromatase activity, which converts testosterone to estradiol at an accelerated rate. We started anastrozole to reduce that conversion and improve his testosterone-to-estradiol ratio, and clomiphene to stimulate his own LH and FSH and with them his endogenous testosterone production. The goal is to use his own machinery rather than bypass it.

Metabolic optimization. An insulin resistance score of 35 is a meaningful brake on healing. Insulin resistance impairs cellular repair signaling, amplifies systemic inflammation, and blunts the growth factor pathways that tissue regeneration depends on. We placed a continuous glucose monitor, not to count carbohydrates obsessively, but to give him real-time feedback on how his specific food choices, meal timing, sleep, and stress affect his glucose. For most patients, two weeks with a CGM changes their relationship with food more durably than any dietary counseling I can provide.

Prong Two: Exogenous Therapeutics

Only after we had a plan to optimize the terrain did we turn to exogenous therapeutics. This is where the peptides enter the conversation, specifically BPC-157, TB-500, and the broader Wolverine stack he’d been asking about. We also added oral specialized pro-resolving mediators (SPMs) to support inflammation resolution, locally injected exosomes for paracrine tissue repair signaling, and PRP for targeted growth factor delivery to the injury site.

That part deserves its own deep dive, which is exactly what Part 2 of this 3-part series will be. We’ll go compound by compound: mechanism, evidence quality, safety profile, quality assurance considerations, and cost.

Subscribe now

THE TAKEAWAY FROM PART ONE

The Wolverine stack might be the right answer for you. Then again, it might not be. Early safety data appear promising, but are they from a reliable compounding pharmacy with third-party quality assurance? The clinical data are thin. Can you afford the monthly out-of-pocket expense for a full treatment program? What is your risk tolerance? What does your terrain look like?

Just because “we don’t know” doesn’t mean “we don’t engage.” It means asking the right questions in the right order. It means looking at the whole person and not just the injury. It means being honest about what you’re comparing against, including the risks of the standard-of-care options we’ve stopped questioning.

Fix the soil before you plant the seeds.

In Part 2, we get into the peptides themselves. See you there.

Before you read Part 2: what’s your instinct when you hear about a therapy that “works for everyone at the gym” but has no clinical trial data? Where does your default skepticism start, and has it ever gotten in the way of something that could have helped you? Tell me in the comments.

Leave a comment

Upcoming

Part 2 — The Wolverine Stack: BPC-157, TB-500, CJC-1295

Part 3 — Growth Hormone boosters: Ipamorelin, Sermorelin, Tesamorelin

References

1. Besedovsky, Luciana, et al. “Auditory Closed-Loop Stimulation of EEG Slow Oscillations Strengthens Sleep and Signs of Its Immune-Supportive Function.” Nature Communications 8, no. 1 (December 7, 2017): 14367. https://doi.org/10.1038/s41467-017-02170-30.

2. Holl, R. W., et al. “Thirty-Second Sampling of Plasma Growth Hormone in Man: Correlation with Sleep Stages.” The Journal of Clinical Endocrinology and Metabolism 72, no. 4 (1991): 854–861. https://doi.org/10.1210/jcem-72-4-854.

3. Solomon, Daniel H., et al. “The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial.” The American Journal of Medicine 130, no. 12 (2017): 1415–1422.e4. https://doi.org/10.1016/j.amjmed.2017.06.028.

4. Vasireddi, Nikhil, et al. “Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.” HSS Journal: The Musculoskeletal Journal of Hospital for Special Surgery 21, no. 4 (July 31, 2025): 15563316251355551. https://doi.org/10.1177/15563316251355551.

What does it mean to do that in a body you’ve never fully understood, in a healthcare system that gives you fifteen minutes and calls it medicine, in a culture that has confused optimization with aliveness?

These questions have followed me my entire career, through Stanford, UCSF, and two years of clinical research fellowship learning how to read a study the way a mechanic reads an engine: not just what it says, but what it’s potentially hiding.

They’ve followed me into the backcountry, where I’ve led men through whiteouts at altitude and watched something fall away that no lab panel can measure. Into the circles of men I’ve sat with for years, watching high-performing, outwardly successful human beings discover, often for the first time, that the life they built has an interior that has been waiting for them. Into the exam room, where I’ve learned that a man’s lipid panel and his loneliness are not separate clinical problems.

What I’ve found, again and again: the men who are moving the fastest are often the ones following the wrong track.

Subscribe now

The Problem With What You’ve Been Offered

You’ve been sold two things. Neither is complete.

The first is conventional medicine, which is rigorous, evidence-based, and organized almost entirely around disease management. Your annual physical is screening for catastrophe. It is not a map for how to live. Most of what determines your quality of life at 60, 70, 80 — your muscle mass, your cardiovascular architecture, your hormonal milieu, your capacity for connection — your doctor isn’t measuring, let alone discussing.

The second is the wellness-influencer complex, and it has never been louder or more dangerous. Peptides promoted by people who can’t interpret a pharmacokinetic curve let alone safety or effectiveness. Protocols built on mouse studies and affiliate links. The signal-to-noise ratio is tragic, and the cost isn’t just wasted money. It’s misdirected attention and hope in a finite life.

Neither lane is enough. Most medical voices give you data without meaning. Most wellness voices give you meaning without rigor. You deserve both in the same room, from someone trained to hold them together and prepared to walk the talk.

That is what this substack is.

What I Believe

I believe your biology is specific to you — not to a population mean, not to a guideline written for actuarial convenience, but to your genetics, your history, your body under load, your inflammatory response, your particular kind of stress and the unique way you’ve learned to carry it.

I believe that grip strength is a vital sign and resistance training is medicine. Your 30-year cardiovascular risk is a conversation worth having at 42, not 64. Your psycho-emotional architecture lies underneath your choices as patterns laid down early, running quietly in the background, and ultimately determining whether any of your protocols will hold.

And I believe, with equal conviction, that none of that is enough if the life you’re optimizing isn’t the one you want.

I’ve earned black belts in multiple disciplines, not because I needed credentials, but because martial arts taught me that the body is the first text — that how you move and react under pressure tells you everything about how you’re living. I’ve led men through heli-skiing expeditions in Alaska and couples’ retreats in the desert, not as a side project, but as the same work: taking people to the edge of the familiar until something honest shows up.

The men’s groups I run are called Masculinity, Measured. What happens in them can’t be fully described here. What I can tell you is that men who have won by every conventional measure begin to remember in those rooms. Dreams and aspirations quietly set aside years ago, traded for financial success and the appearance of arrival. Someone finally gave them permission to become whole.

That is the version of medicine I practice. Precise and human. Rigorous and alive.

Subscribe now

Why The Tracker, Why Now

The gap I’m describing — between clinical rigor and the deeper questions that determine whether a man is inhabiting his life — has no owner. I’ve watched it go unaddressed for my entire career.

Not by bad actors. By a system that was never designed to hold it.

The annual physical can’t hold it. The wellness app can’t hold it. The self-help book can’t hold it. The longevity and wellness clinics can’t hold it. And the influencer with 800,000 followers and a peptide stack can’t hold it.

This substack is where that thinking lives. It is the written extension of my clinical practice, clinical research, and my couples’ and men’s group work — the place for what a 15-minute visit cannot contain.

What You’ll Find Here

Every week, I’ll bring the clinical rigor, the honest questions, and the human framework that high-performing men are not getting anywhere else.

Starting June 15th, three times a month — with occasional Substack Live conversations from my practice — I’ll open with a first series on peptides: what the evidence shows, what remains genuinely unknown, and how to navigate a space that is equal parts promising science and predatory noise. I’ll show you how to read a study. I’ll tell you what I use with patients and why. I’ll tell you where I am uncertain, because that’s what intellectual honesty looks like from a physician who isn’t selling anything.

Beyond that, expect:

— Essays on what the data says about how men age — and what you can do about it, specifically and precisely, starting now. Testosterone, cortisol, cardiovascular risk, body composition, grip strength, biological age.

— On male-pattern depression and the ways it disguises itself. On the labs your doctor isn’t running and why they matter.

— The harder questions alongside all of it. What are you numbing? Is the life you’re optimizing the one you want? What would it mean to follow your actual track rather than the one you inherited?

I’m not here to give you another protocol to manage. I’m here to help you see clearly including what’s happening in your body, what’s happening underneath it, and what to do about both.

A Different Kind of Voice

Healthcare has needed this for a long time.

We don’t need another guru or someone with a supplement line, or a public health official telling us what works at the population level, i.e., promulgating medicine for the average.

Someone writing to you… the specific man in the specific body with the specific life that is, in some essential way, uninhabited.

Someone trained to read the literature without being seduced by it, and trained by years of sitting with men at the edge of change to know that the literature is never the whole story.

Someone who’s spent 50 years studying martial arts, 30 years practicing yoga and meditation, and a lifetime as a seeker. Someone who runs his own N-of-1 experiments to figure out what works and what does not work in this moment, in this time, in this body.

That’s what I’m offering. I hope it’s what you’ve been waiting for.

I’ll see you June 15th.

With respect and a full heart —

Brad Jacobs MD

Brad Jacobs, MD is a Stanford/UCSF-trained internist, clinical researcher, and founder of Blue Wave Medicine in San Francisco. He leads Masculinity, Measured men’s groups, heli-skiing and couples retreats, and holds multiple black belts. The Tracker is his weekly publication at the intersection of precision medicine, masculine psychology, and the questions that determine whether high-performing men are alive inside their own lives.